Aurobindo is pleased to announce that it has entered into an agreement with MS Gilead Sciences, Foster city CA, USA. This agreement will enable Aurobindo to manufacture and market generic versions of their Brand Viread (Tenofovir disoproxil fumerate) in 95 countries under Gilead Access program. The country classification is rated according to the Human Development index and includes high prevalence focus countries in Africa and Asia including India. The company can also seek marketing authorizations in other countries for the said product.

The licensing agreements include a technology transfer to enable expeditious production of large volumes of high quality generic versions of Tenofovir DF. Aurobindo meets the required national and international regulatory standards, which is statutory for such a type of licensing.

Tenofovir belongs to NRTI class of ARV’s, and is found to be the best in its class. Tenofovir is generally used in combination with another NNRTI. The combination improves compliance dramatically as it is once a day dosage.

With Aurobindo’s ability to resolve complex chemistry issues, and 24 USFDA approved products in ARV segment, the company is in the forefront of providing generic versions at low cost and help reach large number of patients. With this agreement the Company further reinforces its chairman’s address at the UN Hqrs, of striving to make ARV’s access across the affected countries in quick time.

Tenofovir commands a market of over 1300 mio in usd world over. 

Sourced From: Aurobindo Pharma Limited